Multi-specific protein molecules and uses thereof
AssigneeTrio Pharmaceuticals, Inc.
InventorsShivarupam BHOWMIK, William A. BRADY
Life of this patent
Estimating the term…
Abstract
Disclosed herein are multi-specific binding polypeptide molecules (e.g., multi-specific antibodies) that can interact with a tumor cell and an immunosuppressive cell. In some embodiments, also described herein are methods for treating one or more diseases or conditions (e.g., cancers) using the multi-specific binding polypeptides (e.g., multi-specific antibodies).
Claims65
A multi-specific antibody comprising a tumor binding moiety that specifically binds to a tumor-associated antigen and an immune cell binding moiety that specifically binds to an antigen expressed on an immunosuppressive cell.
A nucleic acid encoding a multi-specific antibody comprising an immunoglobulin heavy chain comprising an amino acid sequence at least about 90%, 95%, 97%, 98%, 99%, or 100% identical to or consist of the amino acid sequence set forth in SEQ ID NOs:
- 7 or 75-77;
- and optionally an immunoglobulin light chain at least about 90%, 95%, 97%, 98%, 99%, or 100% identical to or consist of the amino acid sequence set forth in SEQ ID NO:
- 8.
A nucleic acid encoding a multi-specific antibody comprising an immunoglobulin heavy chain comprising an amino acid sequence at least about 90%, 95%, 97%, 98%, 99%, or 100% identical to or consist of the amino acid sequence set forth in SEQ ID NOs:
- 79-83;
- and optionally an immunoglobulin light chain at least about 90%, 95%, 97%, 98%, 99%, or 100% identical to or consist of the amino acid sequence set forth in SEQ ID NO:
- 80.
A nucleic acid encoding a multi-specific antibody comprising an immunoglobulin heavy chain comprising an amino acid sequence at least about 90%, 95%, 97%, 98%, 99%, or 100% identical to or consist of the amino acid sequence set forth in SEQ ID NOs:
- 84-88;
- and optionally an immunoglobulin light chain at least about 90%, 95%, 97%, 98%, 99%, or 100% identical to or consist of the amino acid sequence set forth in SEQ ID NO:
- 85.
A nucleic acid encoding a multi-specific antibody comprising an immunoglobulin heavy chain comprising an amino acid sequence at least about 90%, 95%, 97%, 98%, 99%, or 100% identical to or consist of the amino acid sequence set forth in SEQ ID NOs:
- 89, 91, or 93;
- and optionally an immunoglobulin light chain at least about 90%, 95%, 97%, 98%, 99%, or 100% identical to or consist of the amino acid sequence set forth in SEQ ID NO:
- 90, 92, or 94.
A method of inducing immunosuppressive cell killing in a subject in need thereof, comprising administering an antibody-cytotoxin conjugate that specifically binds to an antigen expressed on an immunosuppressive cell, thereby killing the immunosuppressive cell in the subject.
A method of activating tumor cell-killing immune cells in a subject in need thereof, comprising administering an antibody-cytotoxin conjugate that specifically binds to an antigen expressed on an immunosuppressive cell, thereby killing the immunosuppressive cell and activating the tumor cell-killing immune cells in the subject.
A method of reducing suppression of tumor cell-killing immune cells in a subject in need thereof, comprising administering an antibody-cytotoxin conjugate that specifically binds to an antigen expressed on an immunosuppressive cell, thereby killing the immunosuppressive cell and reducing suppression of the tumor cell-killing immune cells in the subject.
Dependencies are inferred from the claim text.